Filing Flows › Prime Medicine (PRME) › Q3 2025
Prime Medicine (PRME) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 7, 2025
Prime Medicine (PRME) reported revenue of $1.2M for the third quarter 2025 (Q3 2025), +486% from a year earlier and +10% from the quarter before.
Prime Medicine, Q3 2025: revenue $1.2M (+486% year over year), net loss $50.6M, operating cash flow −$35.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | +10% | +486% |
| Operating profit | −$54.0M | — | — |
| Net earnings | −$50.6M | — | — |
| Operating cash flow | −$35.0M | — | — |
What changed
Revenue was $1.2M in Q3 2025, up 486% year over year and up 10% from the previous quarter.
Operating costs exceeded revenue by $54.0M, an operating margin of -4406.0%. Total costs grew 1% against revenue growth of 486%. The quarter ended with a net loss of $50.6M, narrower than the previous quarter's $52.6M loss.
Operating cash flow was −$35.0M. Non-cash charges added back $1.9M of depreciation and amortization and $12.7M of share-based compensation. Capital expenditures of $247K exceeded it, leaving free cash flow of −$35.3M.
Questions
What was Prime Medicine's revenue in the third quarter 2025?
Prime Medicine (PRME) reported revenue of $1.2M for the third quarter 2025 (Q3 2025), +486% from a year earlier and +10% from the quarter before.
Source: Prime Medicine 10-Q on SEC EDGAR.